Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxue Shengfa Capsule is a Traditional Chinese Medicine (TCM) proprietary formula primarily indicated for the treatment of various forms of hair loss, including androgenetic alopecia (AGA) and alopecia areata. The formulation contains several botanical bioactives, including 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (TSG), chlorogenic acid, emodin, ferulic acid, isoimperatorin, and paeoniflorin. Its therapeutic effect is attributed to the modulation of 5α-reductase activity and the regulation of gene expressions such as IGF-1, DKK-1, and TGF-β1 in human dermal papilla cells. Additionally, it has been shown to up-regulate vascular endothelial growth factor (VEGF) expression, which promotes scalp blood vessel neogenesis and improves hair follicle nutrition. While widely used in China, clinical surveillance has been conducted to monitor for potential side effects, most notably drug-induced liver injury (DILI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangxue Shengfa Capsule.